Skip to main content
. Author manuscript; available in PMC: 2010 Feb 19.
Published in final edited form as: Cell Host Microbe. 2009 Feb 19;5(2):137–150. doi: 10.1016/j.chom.2008.12.010

Figure 6. TLR4, MyD88, and PMNs are required for the development of peptidoglycan- or MDP-induced acute arthritis.

Figure 6

(A) Swelling and erythema of ankles and feet in TLR2-/- but not in TLR4-/- mice after intravenous injection of 200 μg of PGN. (B) Arthritis scores and incidence in TLR2-/-, TLR4-/-, and MyD88-/- mice after intravenous injection of 200 μg of PGN or 100 μg of MDP; or in WT mice after intravenous injection of 10 μg of ReLPS; means ± SE of 12-20 mice/group. (C) Expression of chemokine and cytokine mRNA in the feet of TLR4-/- mice after intravenous injection of 100 μg of MDP, determined as in Figure 3. (D) Arthritis scores and incidence in WT mice treated with control IgG or anti-PMN mAb after intravenous injection of 200 μg of PGN or 100 μg of MDP; means ± SE of 10 mice/group. (E) Blood PMNs from untreated TLR4-/- and MyD88-/- mice, in contrast to WT mice, do not express CD11b integrin detected on Western blot.